The interplay of the gut microbiome, tryptophan metabolites, and uremic toxin generation in chronic kidney disease progression
World Advances in Renal Medicine · 02.10.2026 · 2 · 147-160
DOI: 10.25259/warm_16_2026 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Advances in Renal Medicine, online erschienen am 02.10.2026. Verfasst von Tariq Ahmed Zayan und 1 weiteren Autor:innen. Die Arbeit nennt 71 Literaturangaben.
Abstract (Originalsprache)
Chronic kidney disease (CKD) affects roughly 850 million people worldwide, yet the cardiovascular and immune-related mortality that classical uremic markers cannot fully explain remains the central clinical problem. Much of the small-solute uremic toxin pool is now traceable to gut microbial metabolism, and tryptophan-derived metabolites – generated by both bacterial and host pathways – sit at the center of this picture. Across the CKD spectrum, the intestinal microbiome shifts toward proteolytic, indole-generating, and urease-positive taxa while fiber-fermenting commensals decline. Two tryptophan pathways drive most of the downstream injury: The host kynurenine route, amplified by interferon-γ-driven indoleamine 2,3-dioxygenase activation, and the bacterial indole route, which generates indoxyl sulfate (IS), indole-3-acetic acid (IAA), and indole-3-propionic acid (IPA). These metabolites converge on the aryl hydrocarbon receptor but produce opposite outcomes: IS, IAA, and kynurenine drive an injurious Nuclear factor kappa B/NOD-, LRR- and pyrin domain-containing 3/transforming growth factor beta 1 program, while IPA, depleted in CKD, supports gut barrier integrity and dampens inflammation. In adjusted Cox models, IS independently predicts cardiovascular and all-cause mortality (hazard ratio [HR] 2.10/1-standard deviation log-IS, 95% confidence interval [CI] 1.37–3.23) and p-cresyl sulfate predicts renal progression (HR 1.092 per μmol/L, 95% CI 1.060–1.126). Plant-dominant, fiber-rich dietary patterns remain the best-supported intervention; synbiotics produce modest surrogate-level benefit, and oral spherical carbon adsorbent (AST-120) is regionally approved but failed its primary composite endpoint in the multinational EPPIC-1/2 trials. The next generation of trials must use validated biomarker thresholds, ligand-selective interventions, hard renal and cardiovascular endpoints, and cohorts beyond Europe and East Asia.
Zitieren
APA
Zayan, T. A., & Khafagy, H. A. (2026). The interplay of the gut microbiome, tryptophan metabolites, and uremic toxin generation in chronic kidney disease progression. World Advances in Renal Medicine, 2, 147-160. https://doi.org/10.25259/warm_16_2026
Vancouver
Zayan TA, Khafagy HA. The interplay of the gut microbiome, tryptophan metabolites, and uremic toxin generation in chronic kidney disease progression. World Advances in Renal Medicine. 2026;2:147-160. doi:10.25259/warm_16_2026
BibTeX
@article{Zayan2026,
author = {Zayan, Tariq Ahmed and Khafagy, Heba Abouelyazied},
title = {The interplay of the gut microbiome, tryptophan metabolites, and uremic toxin generation in chronic kidney disease progression},
journal = {World Advances in Renal Medicine},
year = {2026},
volume = {2},
pages = {147--160},
doi = {10.25259/warm_16_2026}
}
EUVIMED